Junwu Shen

571 total citations
9 papers, 142 citations indexed

About

Junwu Shen is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Hematology. According to data from OpenAlex, Junwu Shen has authored 9 papers receiving a total of 142 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Genetics and 4 papers in Hematology. Recurrent topics in Junwu Shen's work include Hemoglobinopathies and Related Disorders (4 papers), Iron Metabolism and Disorders (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Junwu Shen is often cited by papers focused on Hemoglobinopathies and Related Disorders (4 papers), Iron Metabolism and Disorders (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Junwu Shen collaborates with scholars based in United Kingdom, United States and Egypt. Junwu Shen's co-authors include Yurdanur Kılınç, Amal El‐Beshlawy, Mohsen Saleh Elalfy, Dany Habr, John B. Porter, Yeşim Aydınok, Silverio Perrotta, Antonis Kattamis, Zeynep Karakaş and Maria Domenica Cappellini and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular Cancer Therapeutics.

In The Last Decade

Junwu Shen

9 papers receiving 138 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junwu Shen United Kingdom	5	96	91	34	30	22	9	142
Rosario Di Maggio Italy	8	168 1.8×	156 1.7×	48 1.4×	17 0.6×	25 1.1×	25	214
Marine Weill Switzerland	6	90 0.9×	70 0.8×	22 0.6×	16 0.5×	40 1.8×	13	138
GiovanBattista Leoni Italy	6	320 3.3×	295 3.2×	114 3.4×	15 0.5×	9 0.4×	6	351
Е. А. Chernyavskaya Russia	2	64 0.7×	146 1.6×	6 0.2×	5 0.2×	33 1.5×	8	215
Angela Vitrano Italy	9	229 2.4×	210 2.3×	63 1.9×	26 0.9×	26 1.2×	23	288
Francesca Granata Italy	11	40 0.4×	43 0.5×	91 2.7×	61 2.0×	232 10.5×	32	320
Holly Coles United Kingdom	2	72 0.8×	43 0.5×	28 0.8×	18 0.6×	5 0.2×	3	99
Lewis Nasr United States	9	29 0.3×	80 0.9×	18 0.5×	7 0.2×	26 1.2×	27	139
Justin Geier United States	2	22 0.2×	46 0.5×	3 0.1×	40 1.3×	34 1.5×	2	102
G. Barosi Italy	6	50 0.5×	41 0.5×	3 0.1×	6 0.2×	15 0.7×	11	101

Countries citing papers authored by Junwu Shen

Since Specialization

Citations

This map shows the geographic impact of Junwu Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junwu Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junwu Shen more than expected).

Fields of papers citing papers by Junwu Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junwu Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junwu Shen. The network helps show where Junwu Shen may publish in the future.

Co-authorship network of co-authors of Junwu Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Junwu Shen. A scholar is included among the top collaborators of Junwu Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junwu Shen. Junwu Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Popat, Sanjay, Benjamin Solomon, Geoffrey Liu, et al.. (2025). Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations

Johnson, Melissa L., Enriqueta Felip, Sai‐Hong Ignatius Ou, et al.. (2023). Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors. Molecular Cancer Therapeutics. 22(12_Supplement). B154–B154. 3 indexed citations

Reckamp, Karen L., Huamao Mark Lin, Pingkuan Zhang, et al.. (2022). Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L. Current Medical Research and Opinion. 38(9). 1587–1593. 3 indexed citations

Kim, Edward S., Fabrice Barlési, Tony Mok, et al.. (2021). ALTA-2: Phase II Study of Brigatinib in Patients with ALK-Positive, Advanced Non-Small-Cell Lung Cancer Who Progressed on Alectinib or Ceritinib. Future Oncology. 17(14). 1709–1719. 10 indexed citations

Smith, Matthew, Chris Parker, Bertrand Tombal, et al.. (2016). ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 34(15_suppl). TPS5088–TPS5088. 7 indexed citations

Aydınok, Yeşim, Antonis Kattamis, Maria Domenica Cappellini, et al.. (2015). Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 125(25). 3868–3877. 71 indexed citations

Pennell, Dudley J., John B. Porter, Antonio Piga, et al.. (2014). Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology. 90(2). 91–96. 35 indexed citations

Pennell, Dudley J., John B. Porter, Antonio Piga, et al.. (2013). Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension. Blood. 122(21). 1018–1018. 4 indexed citations

Aydınok, Yeşim, Antonis Kattamis, Maria Domenica Cappellini, et al.. (2013). Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION). Blood. 122(21). 2257–2257. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact